000 01447 a2200421 4500
005 20250512090619.0
264 0 _c19711116
008 197111s 0 0 eng d
022 _a0007-1323
024 7 _a10.1002/bjs.1800580904
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aAubrey, D A
245 0 0 _aThe effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH582) on benign prostatic hypertrophy.
_h[electronic resource]
260 _bThe British journal of surgery
_cSep 1971
300 _a648-52 p.
_bdigital
500 _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article
650 0 4 _aAcid Phosphatase
_xblood
650 0 4 _aAged
650 0 4 _aClinical Trials as Topic
650 0 4 _aDrug Hypersensitivity
650 0 4 _aHumans
650 0 4 _aInjections, Intramuscular
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aOrgan Size
650 0 4 _aPlacebos
650 0 4 _aPregnanes
_xadverse effects
650 0 4 _aProgestins
_xadverse effects
650 0 4 _aProstate
_xdiagnostic imaging
650 0 4 _aProstatic Hyperplasia
_xdrug therapy
650 0 4 _aPyuria
_xcomplications
650 0 4 _aThyroid Gland
_xdrug effects
650 0 4 _aUrinary Catheterization
650 0 4 _aUrography
700 1 _aKhosla, T
773 0 _tThe British journal of surgery
_gvol. 58
_gno. 9
_gp. 648-52
856 4 0 _uhttps://doi.org/10.1002/bjs.1800580904
_zAvailable from publisher's website
999 _c4111547
_d4111547